Welcome to our dedicated page for P3 Health Partners news (Ticker: $PIII), a resource for investors and traders seeking the latest updates and insights on P3 Health Partners stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect P3 Health Partners's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of P3 Health Partners's position in the market.
P3 Health Partners Inc. (NASDAQ: PIII) reported the approval of employment inducement equity grants to Aric Coffman, M.D., who will serve as the Chief Executive Officer and President. The grants include a stock option for 12,100,000 Class A shares of Common Stock and a restricted stock unit (RSU) award for 4,400,000 shares of Common Stock. Both awards are subject to vesting conditions based on Dr. Coffman's employment and the company's performance.
P3 Health Partners announced its first quarter 2024 results, showcasing a 29% year-over-year revenue growth. Dr. Aric Coffman joined as CEO, with a focus on achieving profitability in 2024. The company reaffirmed its 2024 guidance, aiming for Adjusted EBITDA positivity. Total revenue was $388.5 million, capitated revenue saw a significant increase, but gross profit saw a decline. The net loss improved slightly, while Adjusted EBITDA loss also increased. Fiscal 2024 guidance outlines ambitious targets for at-risk members, total revenues, medical margin, and Adjusted EBITDA.
P3 Health Partners Inc. announced that Dr. Aric Coffman has been appointed as the new CEO, effective May 8, 2024, succeeding Dr. Sherif Abdou. Dr. Abdou will continue as a Strategic Advisor and Board member. Dr. Coffman brings extensive experience in value-based care and healthcare delivery for seniors, with a successful track record in leadership roles. The appointment reflects the company's focus on growth and success in the value-based care sector.
P3 Health Partners Inc. (NASDAQ: PIII) announced the schedule for its first quarter 2024 earnings release and conference call. The financial results will be released on May 8, 2024, followed by a conference call to discuss the results at 1:30pm PT/ 4:30pm ET on the same day.